MedCity Influencers Small Changes, Big Impact: Integrating Culturally Sensitive Communication Into Diabetes Care for Medicaid Members By Elizabeth Hamacher
BioPharma, Pharma Roche Lines Up $2.7B Acquisition to Join Chase for New Diabetes, Obesity Drugs By Frank Vinluan
BioPharma, Pharma Carmot’s IPO Filing Makes Case for Bias in Drugging Key Obesity, Diabetes Targets By Frank Vinluan
BioPharma, Pharma Novo Nordisk’s Star Diabetes & Obesity Drug Shows Promise in Kidney Disease By Frank Vinluan
Devices & Diagnostics Abbott-Bigfoot Deal Proves That Diabetes Is a Hot Area for Digital Health Investment By Katie Adams
BioPharma, Pharma Twice Rejected Diabetes Drug/Device Product Gets New Chance at Startup i2o By Frank Vinluan
Consumer / Employer, Health Tech Amazon’s Automatic Coupons for Diabetes Products While “Incremental” Will Still Be a “Gamechanger,” Experts Say By Marissa Plescia
BioPharma, Devices & Diagnostics FDA Authorizes Better Therapeutics Mobile App for Treating Type 2 Diabetes By Frank Vinluan
BioPharma, Pharma A Startup Wins the First FDA Approval of a Cell Therapy for Type 1 Diabetes By Frank Vinluan
BioPharma, Pharma AstraZeneca Teams Up With Startup Quell in Type 1 Diabetes, IBD Cell Therapy Pact By Frank Vinluan
BioPharma, Pharma After FDA Miss in Diabetes, Lexicon Lands Long-Awaited Approval in Heart Failure By Frank Vinluan
MedCity Influencers Is It Possible To Provide Equitable Nutritional Care for Diabetes and Obesity? By Gretchen Zimmermann
BioPharma, Pharma Eli Lilly Unloads Emergency Nasal Spray Diabetes Drug for $500M Up Front By Frank Vinluan
BioPharma, Pharma Vertex Pays CRISPR Therapeutics $100M to Bring Gene-Editing to Type 1 Diabetes By Frank Vinluan
